Oncobiologics, Inc. (NASDAQ:OTLK) Given Average Rating of “Hold” by Analysts

Shares of Oncobiologics, Inc. (NASDAQ:OTLK) have been given an average rating of “Hold” by the six brokerages that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $6.50.

A number of research analysts have recently issued reports on OTLK shares. Ascendiant Capital Markets reduced their price objective on Oncobiologics from $21.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, September 22nd. Chardan Capital restated a “neutral” rating and set a $3.00 target price on shares of Oncobiologics in a report on Thursday, August 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncobiologics in a research note on Tuesday, December 2nd. HC Wainwright reiterated a “neutral” rating on shares of Oncobiologics in a research report on Tuesday, September 30th. Finally, Guggenheim lowered Oncobiologics from a “buy” rating to a “neutral” rating in a research note on Thursday, August 28th.

Oncobiologics Stock Performance

OTLK stock opened at $2.05 on Monday. The firm has a market cap of $91.06 million, a P/E ratio of -3.60 and a beta of 0.17. The firm’s fifty day moving average is $1.44 and its 200 day moving average is $1.64. Oncobiologics has a 52 week low of $0.79 and a 52 week high of $3.39.

Institutional Trading of Oncobiologics

Large investors have recently modified their holdings of the business. Goldman Sachs Group Inc. grew its stake in Oncobiologics by 74.1% in the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after purchasing an additional 44,063 shares during the period. AQR Capital Management LLC boosted its holdings in shares of Oncobiologics by 42.7% during the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after buying an additional 25,351 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its holdings in shares of Oncobiologics by 865.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock valued at $39,000 after buying an additional 21,941 shares in the last quarter. 11.20% of the stock is owned by institutional investors.

Oncobiologics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.